For comments, suggestions
Created with Raphaël 2.1.0 09.10.2015 Formal examination (assignment of filing date) 04.11.2015 Preliminary and substantive examination 30.09.2016 Publication of the decision of grant (B1) 31.03.2017 Completion of the opposition filing period 30.04.2017 Issuance of patent (C1) 09.10.2020 Valid until 30.04.2022 Publication of the decision of forfeiture, the term of re-establishment has expired

Patent lapsed


(11)Number of the document4434
(21)Number of the applicationa 2015 0097
(22)Filing date of the application2015.10.09
 Date of filing the request for examination (de fond) 09.10.2015
(71)Name(s) of applicant(s), code of the countryUNIVERSITATEA DE STAT DIN MOLDOVA, MD;
(72)Name(s) of inventor(s), code of the countryPAHOLNITCAIA Anastasia, MD; POIRIER Donald, CA; TAPCOV Victor, MD; GULEA Aurelian, MD;
(73)Name(s) of owner(s), code of the countryUNIVERSITATEA DE STAT DIN MOLDOVA, MD;
(54)Title of the inventionUse of N'-[1-(2-pyridyl)ethylidene]morpholin-4-carbothiohydrazide as a human myeloid leukemia HL-60 cell proliferation inhibitor
(13)Kind-of-document code
C1, BOPI 04/2017
B1, BOPI 09/2016
(51)International Patent Classification A61K 31/4433 (2006.01); A61K 31/175 (2006.01); A61P 35/02 (2006.01);
(19)CountryMD
(45)Date of publication of patent granting decision:2016.09.30
(47)Date of issuance of patent2017.04.30
 Substantive examiner(s)LEVIŢCHI Svetlana, JOVMIR Tudor
 Payment for maintenance up to the date2020.10.09
 Date of patent termination2020.10.09
 Date of publication of the termination of patent, with the right of restoration2021.05.31
 Date of publication of the termination of patent, without the right of restoration2022.04.30
Up
/inventions/Details.aspx?id=a%202015%200097